VERV Stock: A Voyage Through Verve Therapeutics Inc’s Finances

The stock market performance of Verve Therapeutics Inc has been fairly unsteady. Over the last year, the company’s stock hit its highest at $23.54 on 02/14/23, while the lowest price during the same time frame was $8.22, recorded on 11/13/23.

52-week price history of VERV Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Verve Therapeutics Inc’s current trading price is -49.83% away from its 52-week high, while its distance from the 52-week low is 43.67%. The stock’s price range for this period has remained between $8.22 and $23.54. The Healthcare sector company’s shares managed to surpass a trading volume of around 1.31 million for the day, which was noticeably lower compared to the shares’ average daily volume of 1.59 million over the last three months.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Financial Performance and Market Capitalization

Verve Therapeutics Inc (VERV) has experienced a quarterly decline of -36.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 927.68M and boasts a workforce of 204 employees.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 12.38, with a change in price of -0.87. Similarly, Verve Therapeutics Inc recorded 1,412,646 in trading volume during the last 100 days, posting a change of -6.86%.

VERV Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for VERV stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.14.

VERV Stock Stochastic Average

As of today, the raw stochastic average of Verve Therapeutics Inc over the past 50 days is 29.82%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 45.73%. Additionally, the Stochastic %K and %D values for the company were 30.34% and 22.63%, respectively, over the past 20 days.

VERV Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant loss of -15.28% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -32.63%. Over the past 30 days, the price of VERV has leaped by -15.16%. And in the last five days, it has surged by 5.35%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts